

- S1. Silvestri, L., Caputo, V., Bellacchio, E., Atorino, L., Dallapiccola, B., Valente, E.M., and Casari, G. 2005. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. *Hum. Mol. Genet.* **14**:3477–3492.
- S2. Petit, A., Kawarai, T., Paitel, E., Sanjo, N., Maj, M., Scheid, M., Chen, F., Gu, Y., Hasegawa, H., Salehi-Rad, S., et al. 2005. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. *J. Biol. Chem.* **280**:34025–34032.
- S3. Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, B.A., and Guo, M. 2006. *Drosophila pink1* is required for mitochondrial function and interacts genetically with parkin. *Nature*.
- S4. Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.M., et al. 2006. Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. *Nature*.
- S5. Tan, J.M., and Dawson, T.M. 2006. Parkin Blushed by PINK1. *Neuron* **50**:527–529.
- S6. Bove, J., Prou, D., Perier, C., and Przedborski, S. 2005. Toxin-induced models of Parkinson's disease. *NeuroRx* **2**:484–494.
- S7. Betarbet, R., Canet-Aviles, R.M., Sherer, T.B., Mastroberardino, P.G., McLendon, C., Kim, J.H., Lund, S., Na, H.M., Taylor, G., Bence, N.F., et al. 2006. Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. *Neurobiol Dis.*
- S8. Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., et al. 2005. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. *Proc. Natl. Acad. Sci. U. S. A.* **102**:3413–3418.
- S9. Shults, C.W. 2004. Mitochondrial dysfunction and possible treatments in Parkinson's disease--a review. *Mitochondrion* **4**:641–648.
- S10. Bender, A., Krishnan, K.J., Morris, C.M., Taylor, G.A., Reeve, A.K., Perry, R.H., Jaros, E., Hersheson, J.S., Betts, J., Klopstock, T., et al. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. *Nat. Genet.*

38:515–517.

S11. Kraytsberg, Y., Kudryavtseva, E., McKee, A.C., Geula, C., Kowall, N.W., and Khrapko, K. 2006. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. *Nat. Genet.* **38:518–520.**

S12. Davidzon, G., Greene, P., Mancuso, M., Klos, K.J., Ahlskog, J.E., Hirano, M., and Dimauro, S. 2006. Early-onset familial parkinsonism due to POLG mutations. *Ann Neurol* **59:859–862.**

S13. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B., et al. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron* **44:601–607.**

S14. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N., et al. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron* **44:595–600.**

S15. Gaig, C., Ezquerro, M., Marti, M.J., Munoz, E., Valldeoriola, F., and Tolosa, E. 2006. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. *Arch Neurol* **63:377–382.**

S16. Kachergus, J., Mata, I.F., Hulihan, M., Taylor, J.P., Lincoln, S., Aasly, J., Gibson, J.M., Ross, O.A., Lynch, T., Wiley, J., et al. 2005. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *Am J Hum Genet* **76:672–680.**

S17. Giasson, B.I., Covy, J.P., Bonini, N.M., Hurtig, H.I., Farrer, M.J., Trojanowski, J.Q., and Van Deerlin, V.M. 2006. Biochemical and pathological characterization of Lrrk2. *Ann Neurol* **59:315–322.**

S18. Khan, N.L., Jain, S., Lynch, J.M., Pavese, N., Abou-Sleiman, P., Holton, J.L., Healy, D.G., Gilks, W.P., Sweeney, M.G., Ganguly, M., et al. 2005. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. *Brain* **128:2786–2796.**

S19. Paisan-Ruiz, C., Lang, A.E., Kawarai, T., Sato, C., Salehi-Rad, S., Fisman, G.K., Al-Khairallah, T., St George-Hyslop, P., Singleton, A., and Rogaeva, E. 2005. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. *Neurology* **65:696–700.**

S20. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L., and Dawson, T.M. 2005. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc. Natl. Acad. Sci. U. S. A.* **102**:16842–16847.

S21. Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H., and Ueffing, M. 2006. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. *Hum. Mol. Genet.* **15**:223–232.

S22. Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M., and Ross, C.A. 2005. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. *Proc. Natl. Acad. Sci. U. S. A.* **102**:18676–18681.

S23. Li, C., and Beal, M.F. 2005. Leucine-rich repeat kinase 2: a new player with a familiar theme for Parkinson's disease pathogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **102**:16535–16536.

S24. Silva, R.M., Kuan, C.Y., Rakic, P., and Burke, R.E. 2005. Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. *Mov Disord* **20**:653–664.

S25. Chen, L., and Feany, M.B. 2005. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. *Nat Neurosci* **8**:657–663.

S26. Yang, Y., Gehrke, S., Haque, M.E., Imai, Y., Kosek, J., Yang, L., Beal, M.F., Nishimura, I., Wakamatsu, K., Ito, S., et al. 2005. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. *Proc. Natl. Acad. Sci. U. S. A.* **102**:13670–13675.

S27. Onyango, I.G., Tuttle, J.B., and Bennett, J.P., Jr. 2005. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H₂O₂-induced neuronal death. *Neurobiol Dis* **20**:141–154.

S28. Lees, A.J., Katzenschlager, R., Head, J., and Ben-Shlomo, Y. 2001. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. *Neurology* **57**:1687–1694.

S29. Holloway, R.G., Shoulson, I., Fahn, S., Kiebertz, K., Lang, A., Marek, K.,

McDermott, M., Seibyl, J., Weiner, W., Musch, B., et al. 2004. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. *Arch Neurol* **61**:1044–1053.

S30. Rascol, O., Brooks, D.J., Korczyn, A.D., De Deyn, P.P., Clarke, C.E., and Lang, A.E. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *N. Engl. J. Med.* **342**:1484–1491.

S31. Chen, J.J., and Oberg, C. 2005. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. *Clin Ther* **27**:1710–1724.

S32. Hauser, R.A., Hubble, J.P., and Truong, D.D. 2003. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. *Neurology* **61**:297–303.

S33. Bara-Jimenez, W., Bibbiani, F., Morris, M.J., Dimitrova, T., Sherzai, A., Mouradian, M.M., and Chase, T.N. 2005. Effects of serotonin 5-HT_{1A} agonist in advanced Parkinson's disease. *Mov Disord* **20**:932–936.

S34. Olanow, C.W., Damier, P., Goetz, C.G., Mueller, T., Nutt, J., Rascol, O., Serbanescu, A., Deckers, F., and Russ, H. 2004. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). *Clin Neuropharmacol* **27**:58–62.

S35. Stocchi, F., Ruggieri, S., Vacca, L., and Olanow, C.W. 2002. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. *Brain* **125**:2058–2066.

S36. Mouradian, M.M. 2005. Should levodopa be infused into the duodenum? *Neurology* **64**:182–183.

S37. Colzi, A., Turner, K., and Lees, A.J. 1998. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. *J Neurol Neurosurg Psychiatry* **64**:573–576.

S38. Lim, E. 2005. A walk through the management of Parkinson's disease. *Ann Acad Med Singapore* **34**:188–195.

S39. Galvez-Jimenez, N. 2005. Advances in the surgical treatment of Parkinson's

disease: emphasis on pallidotomy and deep brain stimulation. In *Scientific basis for the treatment of Parkinson's disease. Second edition*. N. Galvez-Jimenez, editor. London and New York: Taylor & Francis. 151–168.

S40. Benabid, A.L., Chabardes, S., and Seigneuret, E. 2005. Deep-brain stimulation in Parkinson's disease: long-term efficacy and safety - What happened this year? *Curr Opin Neurol* **18**:623–630.

S41. Jenkinson, N., Nandi, D., Aziz, T.Z., and Stein, J.F. 2005. Pedunculopontine nucleus: a new target for deep brain stimulation for akinesia. *Neuroreport* **16**:1875–1876.

S42. Alisauskiene, M., Truffert, A., Vaiciene, N., and Magistris, M.R. 2005. Transcranial magnetic stimulation in clinical practice. *Medicina (Kaunas)* **41**:813–824.

S43. Strafella, A.P., Ko, J.H., and Monchi, O. 2006. Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: The contribution of expectation. *Neuroimage*.

S44. Lomarev, M.P., Kanchana, S., Bara-Jimenez, W., Iyer, M., Wassermann, E.M., and Hallett, M. 2006. Placebo-controlled study of rTMS for the treatment of Parkinson's disease. *Mov Disord* **21**:325–331.

S45. Chaudhuri, K.R., Healy, D.G., and Schapira, A.H. 2006. Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol* **5**:235–245.

S46. Singer, W., Sandroni, P., Opfer-Gehrking, T.L., Suarez, G.A., Klein, C.M., Hines, S., O'Brien P, C., Slezak, J., and Low, P.A. 2006. Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension. *Arch Neurol*.

S47. Hyson, H.C., Johnson, A.M., and Jog, M.S. 2002. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. *Mov Disord* **17**:1318–1320.

S48. Maidment, I., Fox, C., and Boustani, M. 2006. Cholinesterase inhibitors for Parkinson's disease dementia. *Cochrane Database Syst Rev*:CD004747.

S49. Miyasaki, J.M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L.M., Gronseth, G., and Weiner, W.J. 2006. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*.

S50. Wint, D., Okun, M., and Fernandez, H. 2005. Psychosis in Parkinson's disease. In *Scientific basis for the treatment of Parkinson's Disease*. N. Galvez-Jimenez, editor. London and New York: Taylor & Francis. 189–203.

S51. Ondo, W.G., Tintner, R., Voung, K.D., Lai, D., and Ringholz, G. 2005. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. *Mov Disord* **20**:958–963.

S52. Palhagen, S., Heinonen, E., Hagglund, J., Kaugesaar, T., Maki-Ikola, O., and Palm, R. 2006. Selegiline slows the progression of the symptoms of Parkinson disease. *Neurology* **66**:1–7.

S53. Larsen, J.P., Boas, J., and Erdal, J.E. 1999. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group. *Eur J Neurol* **6**:539–547.

S54. Shults, C.W. 2005. Reexamination of the TEMPO Study. *Arch Neurol* **62**:1320; **author reply 1321**.

S55. The Parkinson Study Group. 2002. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. *Arch Neurol* **59**:1937–1943.

S56. Hara, M.R., Thomas, B., Cascio, M.B., Bae, B.I., Hester, L.D., Dawson, V.L., Dawson, T.M., Sawa, A., and Snyder, S.H. 2006. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. *Proc. Natl. Acad. Sci. U. S. A.* **103**:3887–3889.

S57. Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J., Shoulson, I., Carter, J., et al. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* **59**:1541–1550.

S58. NET-PD Investigators. 2006. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology* **66**:664–671.

S59. Lang, A.E., Gill, S., Patel, N.K., Lozano, A., Nutt, J.G., Penn, R., Brooks, D.J., Hotton, G., Moro, E., Heywood, P., et al. 2006. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. *Ann Neurol* **59**:459–466.

S60. Freed, C.R., Greene, P.E., Breeze, R.E., Tsai, W.Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J.O., et al. 2001. Transplantation of

embryonic dopamine neurons for severe Parkinson's disease. *N. Engl. J. Med.* **344**:710–719.

S61. Olanow, C.W., Goetz, C.G., Kordower, J.H., Stoessl, A.J., Sossi, V., Brin, M.F., Shannon, K.M., Nauert, G.M., Perl, D.P., Godbold, J., et al. 2003. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. *Ann Neurol* **54**:403–414.

S62. Hagell, P., Crabb, L., Pogarell, O., Schrag, A., Widner, H., Brooks, D.J., Oertel, W.H., Quinn, N.P., and Lindvall, O. 2000. Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. *Mov Disord* **15**:224–229.

S63. Piccini, P., Pavese, N., Hagell, P., Reimer, J., Bjorklund, A., Oertel, W.H., Quinn, N.P., Brooks, D.J., and Lindvall, O. 2005. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. *Brain* **128**:2977–2986.

S64. Correia, A.S., Anisimov, S.V., Li, J.Y., and Brundin, P. 2005. Stem cell-based therapy for Parkinson's disease. *Ann Med* **37**:487–498.

S65. Taylor, H., and Minger, S.L. 2005. Regenerative medicine in Parkinson's disease: generation of mesencephalic dopaminergic cells from embryonic stem cells. *Curr Opin Biotechnol* **16**:487–492.